NCT03771612View on ClinicalTrials.gov

Inflammation and Daily Life Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

November 9, 2023

Study Completion Date

June 21, 2024

Conditions
Inflammation
Interventions
DRUG

Naproxen

Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)

DRUG

Placebos

Half of the participants will be randomly assigned to receive a placebo pill twice daily

Trial Locations (1)

90095

UCLA Department of Psychology, Los Angeles

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of California, Los Angeles

OTHER